Key result
Short-term treatment with bFGF enhanced collateral development without increasing neointimal accumulation, whereas VEGF exacerbated neointimal thickening without improving collateral flow.
Why the study?
Does short-term treatment with bFGF or VEGF improve myocardial collateral perfusion and induce neointimal accumulation in a canine model of coronary occlusion and vascular injury?
RCT (n=39)
randomized
Does short-term treatment with bFGF or VEGF improve myocardial collateral perfusion and induce neointimal accumulation in a canine model of coronary occlusion and vascular injury?
Short-term systemic treatment with bFGF enhances coronary collateral development without increasing neointimal hyperplasia, supporting its potential clinical investigation in ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Supports bFGF evaluation in ischemic models; leaves open clinical translation from canine data.
Lazarous et al. (1996) conducted an RCT in ameroid-induced occlusion of the left circumflex coronary artery (n=39). basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) vs. saline was evaluated on maximal collateral flow and neointimal accumulation. Short-term treatment with bFGF enhanced collateral development without increasing neointimal accumulation, whereas VEGF exacerbated neointimal thickening without improving collateral flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: